3m Innovative Properties Company

Coley Pharmaceutical Group, Inc.

Joshua R Wurst

Michael J Rice

Tushar A Kshirsagar

Bryon A Merrill

Philip D Heppner

Chad A Haraldson

Kyle J Lindstrom

Shri Niwas

Michael E Danielson

George W Griesgraber

Sarah J Slania

John F Gerster

Ryan B Prince

David S Hays

Maureen Ann Kavanagh

Matthew R Radmer

Sarah A Strong

Karl J Manske

Adam R Wohl

Azim Alan Celebi

Hugues M H Martin

Karl E Benson

Dong-Wei Zhu

Michael D Crandall

Ross E Behling

Ann R Fornof

Gregory J Marszalek

Anthony P Manzara

Scott E Langer

Robert J Webb

Gregory D Lundquist, Jr

Anish Kurian

Robert B Rosner

David J Squire

Sarah Johannessen

Sarah C Johannessen

Sarah C Slania

Robert J Shimanek, Iii

Rhesa M Browning

Sehban Ozair

Robert J Iii Shimanek

Hugues Martin

The present disclosure provides an oil-resistant adhesive comprising a crosslinked copolymer of (meth)acrylic ester monomers, methyl (meth)acrylate monomers, vinyl ester monomers, and a functional monomer selected from one of (meth)acrylic acid, a (meth)acrylamide or a hydroxyalkyl (meth)acrylate monomers.

Oil resistant adhesive

Protected photocrosslinkers and their use in two-stage photocuring of (meth)acrylate monomers is described.

Acrylic adhesive composition from protected photocrosslinking agents

Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.

Alkoxy substituted imidazoquinolines

Thiazoloquinolines and thiazolonaphthyridines with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines

A method of preferentially inducing IFN-&#x3b1; biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-&#x3b1; biosynthesis in an animal are disclosed.

Method of preferentially inducing the biosynthesis of interferon

Described herein is a mixture comprising: a non-self-crosslinking polymer; and a modifying compound comprising at least two different functional groups. The first functional group of the modifying compound is capable of reacting with the non-self-crosslinking polymer and the second functional group is capable of crosslinking with a curing agent. Also, described are compositions, curable polymeric compositions, articles using such curable polymeric compositions, and methods of making cured polymeric compositions.

Polymeric compositions and method of making and articles thereof

Imidazoquinolines and imidazonaphthyridines with a substituent containing a functional group, e.g., an amide, sulfonamide, urea, or heterocyclyl group, at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Substituted imidazoquinolines and imidazonaphthyridines

Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a &#x2014;CH(&#x2014;X&#x2014;R)&#x2014; group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Chiral fused [1,2]imidazo[4,5-c] ring compounds

Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Aryloxy and arylalkyleneoxy substituted imidazoquinolines

Thiazoloquinoline and thiazolonaphthyridine compounds having an aryloxy or arylalkyleneoxy substituent at the 6-, 7-, 8-, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines

Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a &#x2014;CH(&#x2014;X&#x2014;R)-group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Chiral fused [1,2]imidazo[4,5-C] ring compounds

Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Aryl substituted imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.

Aryl substituted imidazoquinolines

Growing community of inventors

North St. Paul, MN, United States of America

Joshua R Wurst